Center for Scientific Review; Amended Notice of Meeting, 28235-28236 [2011-11949]
Download as PDF
erowe on DSK5CLS3C1PROD with NOTICES
Federal Register / Vol. 76, No. 94 / Monday, May 16, 2011 / Notices
the ACA and hence eligible for the Rate
Review Grants. 46 States and 5 U.S.
territories plus the District of Columbia
were awarded grants. CCIIO is seeking
to publish the Cycle II Funding
Opportunity Announcement and
associated grantee reporting
requirements consisting of (4) Quarterly
reports, rate review transaction data
(quarterly), (1) annual report per year,
and (1) final report from all grantees.
This information collection is required
for effective monitoring of grantees and
to fulfill statutory requirements under
Section 2794(b)(1)(a) that requires
grantees, as a condition of receiving a
grant authorized under Section 2794(c),
to report to The Secretary information
about premium increases. Form
Number: CMS–10380 (OCN: 0938–
1121); Frequency: Annually, On
Occasion; Affected Public: Public
Sector: State and Territory
Governments; Number of Respondents:
107; Number of Responses: 1,075; Total
Annual Hours 42,872. (For policy
questions regarding this collection,
contact Jacqueline Roche at 301–492–
4171. For all other issues call (410) 786–
1326.)
To obtain copies of the supporting
statement and any related forms for the
proposed paperwork collections
referenced above, access CMS’ Web site
at https://www.cms.gov/
PaperworkReductionActof1995/PRAL/
list.asp#TopOfPage or e-mail your
request, including your address, phone
number, OMB number, and CMS
document identifier, to
Paperwork@cms.hhs.gov, or call the
Reports Clearance Office at 410–786–
1326.
In commenting on the proposed
information collections please reference
the document identifier or OMB control
number. To be assured consideration,
comments and recommendations must
be submitted in one of the following
ways by July 15, 2011:
1. Electronically. You may submit
your comments electronically to https://
www.regulations.gov. Follow the
instructions for ‘‘Comment or
Submission’’ or ‘‘More Search Options’’
to find the information collection
document(s) accepting comments.
2. By regular mail. You may mail
written comments to the following
address: CMS, Office of Strategic
Operations and Regulatory Affairs,
Division of Regulations Development,
Attention: Document Identifier/OMB
Control Number, Room C4–26–05, 7500
Security Boulevard, Baltimore,
Maryland 21244–1850.
VerDate Mar<15>2010
15:14 May 13, 2011
Jkt 223001
Dated: May 10, 2011.
Martique Jones,
Director, Regulations Development Group,
Division B, Office of Strategic Operations and
Regulatory Affairs.
[FR Doc. 2011–11836 Filed 5–13–11; 8:45 am]
BILLING CODE 4120–01–P
DEPARTMENT OF HEALTH AND
HUMAN SERVICES
Food and Drug Administration
[Docket Nos. FDA–2009–E–0084 and FDA–
2009–E–0086]
Determination of Regulatory Review
Period for Purposes of Patent
Extension; PRISTIQ; Correction and
Reopening of the Comment Period
AGENCY:
Food and Drug Administration,
HHS.
Notice; correction and
reopening of the comment period.
ACTION:
The Food and Drug
Administration (FDA) is correcting
notices concerning FDA’s determination
of the regulatory review period for
PRISTIQ that appeared in the Federal
Registers of August 31, 2010 (75 FR
53314) and September 2, 2010 (75 FR
53969). The documents omitted docket
number FDA–2009–E–0086. This
document corrects those omissions.
Because the comment period for the
notices closed on February 28, 2011,
FDA is reopening the comment period
to allow interested parties to submit
comments or petitions to docket number
FDA–2009–E–0086.
DATES: Submit either electronic or
written comments and written petitions
by June 15, 2011.
ADDRESSES: Submit electronic
comments to https://
www.regulations.gov. Submit written
petitions along with three copies and
written comments to the Division of
Dockets Management (HFA–305), Food
and Drug Administration, 5630 Fishers
Lane, rm. 1061, Rockville, MD 20852.
FOR FURTHER INFORMATION CONTACT:
Beverly Friedman, Office of Regulatory
Policy, Food and Drug Administration,
10903 New Hampshire Ave., Bldg. 51,
rm. 6222, Silver Spring, MD 20993–
0002, 301–796–3602.
SUPPLEMENTARY INFORMATION:
SUMMARY:
I. Correction
In FR Doc. 2010–21586, appearing on
page 53314, in the Federal Register of
Tuesday, August 31, 2010, the following
correction is made:
1. On page 53314, in the first column,
in the heading of the document,
PO 00000
Frm 00027
Fmt 4703
Sfmt 4703
28235
‘‘[Docket No. FDA–2009–E–0084]’’ is
corrected to read ‘‘[Docket Nos. FDA–
2009–E–0084 and FDA–2009–E–0086]’’.
In FR Doc. C1–2010–21586, appearing
on page 53969, in the Federal Register
of Thursday, September 2, 2010, the
following correction is made:
2. On page 53969, in the third
column, in the heading of the
document, ‘‘[Docket No. FDA–2009–E–
0084]’’ is corrected to read ‘‘[Docket Nos.
FDA–2009–E–0084 and FDA–2009–E–
0086]’’.
II. Comments and Petitions
FDA’s notice concerning the Agency’s
determination of the regulatory review
period for PRISTIQ (75 FR 53314)
inadvertently omitted docket number
FDA–2009–E–0086. Because the period
for submitting comments and petitions
closed on February 28, 2011, FDA is
reopening the comment period to
provide the opportunity for interested
parties to submit comments or petitions
to docket number FDA–2009–E–0086.
Interested persons may submit to the
Division of Dockets Management (see
ADDRESSES) electronic or written
comments and written petitions. It is no
longer necessary to send three copies of
mailed comments. However, if you
submit a written petition, you must
submit three copies of the petition.
Identify comments with docket number
FDA–2009–E–0086. Comments and
petitions that have not been made
publicly available on regulations.gov
may be viewed in the Division of
Dockets Management between 9 a.m.
and 4 p.m., Monday through Friday.
Dated: April 28, 2011.
Jane A. Axelrad,
Associate Director for Policy, Center for Drug
Evaluation and Research.
[FR Doc. 2011–11903 Filed 5–13–11; 8:45 am]
BILLING CODE 4160–01–P
DEPARTMENT OF HEALTH AND
HUMAN SERVICES
National Institutes of Health
Center for Scientific Review; Amended
Notice of Meeting
Notice is hereby given of a change in
the meeting of the Neurodifferentiation,
Plasticity, and Regeneration Study
Section, June 1, 2011, 8 a.m. to June 2,
2011, 4 p.m., Westin Alexandria, 400
Courthouse Square, Alexandria, VA
22314 which was published in the
Federal Register on May 9, 2011, 76 FR
26736–26737.
The meeting will be held at the Hotel
Monaco, 480 King Street, Alexandria,
VA 22314. The meeting dates and time
E:\FR\FM\16MYN1.SGM
16MYN1
28236
Federal Register / Vol. 76, No. 94 / Monday, May 16, 2011 / Notices
remain the same. The meeting is closed
to the public.
DEPARTMENT OF HEALTH AND
HUMAN SERVICES
DEPARTMENT OF HEALTH AND
HUMAN SERVICES
National Institutes of Health
National Institutes of Health
National Institute on Aging; Notice of
Closed Meetings
National Cancer Institute; Notice of
Closed Meetings
Pursuant to section 10(d) of the
Federal Advisory Committee Act, as
amended (5 U.S.C. App.), notice is
hereby given of the following meetings.
The meetings will be closed to the
public in accordance with the
provisions set forth in sections
552b(c)(4) and 552b(c)(6), Title 5 U.S.C.,
as amended. The grant applications and
the discussions could disclose
confidential trade secrets or commercial
property such as patentable material,
and personal information concerning
individuals associated with the grant
applications, the disclosure of which
would constitute a clearly unwarranted
invasion of personal privacy.
Pursuant to section 10(d) of the
Federal Advisory Committee Act, as
amended (5 U.S.C. App.), notice is
hereby given of the following meetings.
The meetings will be closed to the
public in accordance with the
provisions set forth in sections
552b(c)(4) and 552b(c)(6), Title 5 U.S.C.,
as amended. The grant applications and
the discussions could disclose
confidential trade secrets or commercial
property such as patentable material,
and personal information concerning
individuals associated with the grant
applications, the disclosure of which
would constitute a clearly unwarranted
invasion of personal privacy.
Name of Committee: Center for Scientific
Review Special Emphasis Panel, Member
Conflict: Reproductive Biology.
Date: May 18, 2011.
Time: 1 p.m. to 4 p.m.
Agenda: To review and evaluate grant
applications.
Place: National Institutes of Health, 6701
Rockledge Drive, Bethesda, MD 20892
(Telephone Conference Call).
Contact Person: Robert Garofalo, PhD,
Scientific Review Officer, Center for
Scientific Review, National Institute of
Health, 6701 Rockledge Drive, Room 6156,
MSC 7892, Bethesda, MD 20892, 301–435–
1043, garofalors@csr.nih.gov.
This notice is being published less than 15
days prior to the meeting due to the timing
limitations imposed by the review and
funding cycle.
(Catalogue of Federal Domestic Assistance
Program Nos. 93.306, Comparative Medicine;
93.333, Clinical Research, 93.306, 93.333,
93.337, 93.393–93.396, 93.837–93.844,
93.846–93.878, 93.892, 93.893, National
Institutes of Health, HHS)
Name of Committee: National Institute on
Aging Special Emphasis Panel, Pathology of
Alzheimer’s Disease.
Date: June 29, 2011.
Time: 12 p.m. to 4 p.m.
Agenda: To review and evaluate grant
applications.
Place: National Institute on Aging,
Gateway Building, 7201 Wisconsin Avenue,
Suite 2C212, Bethesda, MD 20892,
(Telephone Conference Call).
Contact Person: Alexander Parsadanian,
PhD, Scientific Review Officer, National
Institute on Aging, Gateway Building 2C/212,
7201 Wisconsin Avenue, Bethesda, MD
20892, 301–496–9666,
parsadaniana@nia.nih.gov.
Name of Committee: National Institute on
Aging Special Emphasis Panel, Oxidative
Stress and Aging.
Date: July 13, 2011.
Time: 12 p.m. to 4 p.m.
Agenda: To review and evaluate grant
applications.
Place: National Institute on Aging,
Gateway Building, 7201 Wisconsin Avenue,
Suite 2C212, Bethesda, MD 20892,
(Telephone Conference Call).
Contact Person: Alexander Parsadanian,
PhD, Scientific Review Officer, National
Institute on Aging, Gateway Building 2C/212,
7201 Wisconsin Avenue, Bethesda, MD
20892, 301–496–9666,
parsadaniana@nia.nih.gov.
(Catalogue of Federal Domestic Assistance
Program Nos. 93.866, Aging Research,
National Institutes of Health, HHS)
Dated: May 11, 2011.
Jennifer S. Spaeth,
Director, Office of Federal Advisory
Committee Policy.
Dated: May 10, 2011.
Jennifer S. Spaeth,
Director, Office of Federal Advisory
Committee Policy.
[FR Doc. 2011–11938 Filed 5–13–11; 8:45 am]
[FR Doc. 2011–11943 Filed 5–13–11; 8:45 am]
BILLING CODE 4140–01–P
BILLING CODE 4140–01–P
Name of Committee: National Cancer
Institute Special Emphasis Panel, Cancer
Prevention Research Small Grant Program
(R03).
Date: July 7–8, 2011.
Time: 8 a.m. to 5 p.m.
Agenda: To review and evaluate grant
applications.
Place: Bethesda North Marriott Hotel &
Conference Center, 5701 Marinelli Road,
Bethesda, MD 20852.
Contact Person: Gerald G. Lovinger, PhD,
Scientific Review Administrator, Special
Review and Logistics Branch, Division of
Extramural Activities, National Cancer
Institute, 6116 Executive Blvd., Room 8101,
Bethesda, MD 20892–8329, 301/496–7987,
lovingeg@mail.nih.gov.
Name of Committee: National Cancer
Institute Special Emphasis Panel,
Collaborative Research in Integrative Cancer
Biology and the Tumor Microenvironment
(U01).
Date: July 19, 2011.
Time: 8 a.m. to 6 p.m.
Agenda: To review and evaluate grant
applications.
Place: Bethesda North Marriott Hotel &
Conference Center, 5701 Marinelli Road,
Bethesda, MD 20852.
Contact Person: Viatcheslav A
Soldatenkov, M.D., PhD, Scientific Review
Officer, Special Review and Logistics Branch,
Division of Extramural Activities, National
Cancer Institute, 6116 Executive Blvd., Room
8057, Bethesda, MD 20892–8329, 301–451–
4758, soldatenkovv@mail.nih.gov.
(Catalogue of Federal Domestic Assistance
Program Nos. 93.392, Cancer Construction;
93.393, Cancer Cause and Prevention
Research; 93.394, Cancer Detection and
Diagnosis Research; 93.395, Cancer
Treatment Research; 93.396, Cancer Biology
Research; 93.397, Cancer Centers Support;
93.398, Cancer Research Manpower; 93.399,
Cancer Control, National Institutes of Health,
HHS)
Dated: May 10, 2011.
Jennifer S. Spaeth,
Director, Office of Federal Advisory
Committee Policy.
[FR Doc. 2011–11949 Filed 5–13–11; 8:45 am]
BILLING CODE 4140–01–P
DEPARTMENT OF HEALTH AND
HUMAN SERVICES
National Institutes of Health
Center for Scientific Review; Notice of
Closed Meeting
erowe on DSK5CLS3C1PROD with NOTICES
Pursuant to section 10(d) of the
Federal Advisory Committee Act, as
amended (5 U.S.C. App.), notice is
hereby given of the following meeting.
The meeting will be closed to the
public in accordance with the
provisions set forth in sections
552b(c)(4) and 552b(c)(6), Title 5 U.S.C.,
as amended. The grant applications and
the discussions could disclose
confidential trade secrets or commercial
property such as patentable material,
and personal information concerning
individuals associated with the grant
applications, the disclosure of which
would constitute a clearly unwarranted
invasion of personal privacy.
VerDate Mar<15>2010
15:14 May 13, 2011
Jkt 223001
PO 00000
Frm 00028
Fmt 4703
Sfmt 4703
E:\FR\FM\16MYN1.SGM
16MYN1
Agencies
[Federal Register Volume 76, Number 94 (Monday, May 16, 2011)]
[Notices]
[Pages 28235-28236]
From the Federal Register Online via the Government Printing Office [www.gpo.gov]
[FR Doc No: 2011-11949]
-----------------------------------------------------------------------
DEPARTMENT OF HEALTH AND HUMAN SERVICES
National Institutes of Health
Center for Scientific Review; Amended Notice of Meeting
Notice is hereby given of a change in the meeting of the
Neurodifferentiation, Plasticity, and Regeneration Study Section, June
1, 2011, 8 a.m. to June 2, 2011, 4 p.m., Westin Alexandria, 400
Courthouse Square, Alexandria, VA 22314 which was published in the
Federal Register on May 9, 2011, 76 FR 26736-26737.
The meeting will be held at the Hotel Monaco, 480 King Street,
Alexandria, VA 22314. The meeting dates and time
[[Page 28236]]
remain the same. The meeting is closed to the public.
Dated: May 10, 2011.
Jennifer S. Spaeth,
Director, Office of Federal Advisory Committee Policy.
[FR Doc. 2011-11949 Filed 5-13-11; 8:45 am]
BILLING CODE 4140-01-P